Publicador de continguts

Resistència antimicrobiana

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

Durada
01/03/2015 - 28/02/2020
Coordinador
Jordi Vila
Finançadors
Innovative Medicines Iniciatives 2 (IMI-2)

Infections caused by bacteria known as ‘carbapenem-resistant enterobacteriaceae’ (CRE) are resistant to most available antibiotics and are so difficult to treat they are considered to be one of the most dangerous drug-resistant bacteria in the world. Worryingly, cases of CRE infections are on the rise in Europe and globally.

The COMBACTE-CARE project aims to shed new light on the best ways to understand and treat CRE infections. It will also run clinical trials of a novel antibiotic combination product designed to tackle a sub-type of CRE infections for which there are limited or no treatment options.

Altres projectes

INCENTIVE

Indo-European Consortium for Next Generation Influenza Vaccine Innovation

FLAVOBAC

Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

ENDÈMIC

Community knowledge generation through scientific culture, urban ecology and art